首页> 美国卫生研究院文献>Protein Science : A Publication of the Protein Society >Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimers amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities.
【2h】

Crystal structures of bovine chymotrypsin and trypsin complexed to the inhibitor domain of Alzheimers amyloid beta-protein precursor (APPI) and basic pancreatic trypsin inhibitor (BPTI): engineering of inhibitors with altered specificities.

机译:牛胰凝乳蛋白酶和胰蛋白酶的晶体结构与阿尔茨海默氏淀粉样β蛋白前体(APPI)和碱性胰胰蛋白酶抑制剂(BPTI)的抑制剂结构域复合:特异性改变的抑制剂工程。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The crystal structures of the inhibitor domain of Alzheimer's amyloid beta-protein precursor (APPI) complexed to bovine chymotrypsin (C-APPI) and trypsin (T-APPI) and basic pancreatic trypsin inhibitor (BPTI) bound to chymotrypsin (C-BPTI) have been solved and analyzed at 2.1 A, 1.8 A, and 2.6 A resolution, respectively. APPI and BPTI belong to the Kunitz family of inhibitors, which is characterized by a distinctive tertiary fold with three conserved disulfide bonds. At the specificity-determining site of these inhibitors (P1), residue 15(I)4 is an arginine in APPI and a lysine in BPTI, residue types that are counter to the chymotryptic hydrophobic specificity. In the chymotrypsin complexes, the Arg and Lys P1 side chains of the inhibitors adopt conformations that bend away from the bottom of the binding pocket to interact productively with elements of the binding pocket other than those observed for specificity-matched P1 side chains. The stereochemistry of the nucleophilic hydroxyl of Ser 195 in chymotrypsin relative to the scissile P1 bond of the inhibitors is identical to that observed for these groups in the trypsin-APPI complex, where Arg 15(I) is an optimal side chain for tryptic specificity. To further evaluate the diversity of sequences that can be accommodated by one of these inhibitors, APPI, we used phage display to randomly mutate residues 11, 13, 15, 17, and 19, which are major binding determinants. Inhibitors variants were selected that bound to either trypsin or chymotrypsin. As expected, trypsin specificity was principally directed by having a basic side chain at P1 (position 15); however, the P1 residues that were selected for chymotrypsin binding were His and Asn, rather than the expected large hydrophobic types. This can be rationalized by modeling these hydrophilic side chains to have similar H-bonding interactions to those observed in the structures of the described complexes. The specificity, or lack thereof, for the other individual subsites is discussed in the context of the "allowed" residues determined from a phage display mutagenesis selection experiment.
机译:与牛胰凝乳蛋白酶(C-APPI)和胰蛋白酶(T-APPI)以及与胰凝乳蛋白酶(C-BPTI)结合的碱性胰胰蛋白酶抑制剂(BPTI)形成复合物的阿尔茨海默氏淀粉样蛋白前体(APPI)抑制剂域的晶体结构具有分别以2.1 A,1.8 A和2.6 A的分辨率进行了解析和分析。 APPI和BPTI属于Kunitz抑制剂家族,其特征是具有三个保守的二硫键的独特三级折叠。在这些抑制剂(P1)的特异性确定位点,残基15(I)4在APPI中为精氨酸,在BPTI中为赖氨酸,残基类型与胰凝乳蛋白酶疏水性相反。在胰凝乳蛋白酶复合物中,抑制剂的Arg和Lys P1侧链采用从结合袋底部弯曲的构象,以与结合袋中的元件有效相互作用,而不是特异性匹配的P1侧链所观察到的元件。胰凝乳蛋白酶中Ser 195的Ser 195亲核羟基相对于抑制剂的易裂P1键的立体化学与在胰蛋白酶-APPI复合物中这些基团观察到的立体化学相同,其中Arg 15(I)是胰蛋白酶特异性的最佳侧链。为了进一步评估这些抑制剂之一APPI可以容纳的序列的多样性,我们使用噬菌体展示来随机突变残基11、13、15、17和19,它们是主要的结合决定簇。选择与胰蛋白酶或胰凝乳蛋白酶结合的抑制剂变体。如预期的那样,胰蛋白酶特异性主要是通过在P1处有一个基本侧链(位置15)来指导的;但是,选择用于胰凝乳蛋白酶结合的P1残基是His和Asn,而不是预期的大疏水类型。可以通过对这些亲水性侧链进行建模以使其具有与所述复合物的结构中观察到的相似的氢键相互作用来使其合理化。在从噬菌体展示诱变选择实验确定的“允许”残基的背景下讨论了对其他单个亚位点的特异性或缺乏特异性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号